Evidence map›Paper›PMID 41698721›Full record

ArticleBMJ open2026

Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial.

Manabu Shimomura, Sho Ishikawa, Masashi Miguchi, Katsunori Shinozaki, Satoshi Ikeda, Hironori Kobayashi, Masahiro Nakahara, Daisuke Sumitani, Wataru Shimizu, Mohei Kohyama and 13 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Manabu ShimomuraDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan mshimo@hiroshima-u.ac.jp.ORCID http://orcid.org/0000-0001-8078-0091
Sho IshikawaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Masashi MiguchiDepartment of Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Katsunori ShinozakiDivision of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Satoshi IkedaDepartment of Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Hironori KobayashiDepartment of Surgery, Hiroshima Memorial Hospital, Hiroshima, Japan.
Masahiro NakaharaDepartment of Surgery, Onomichi General Hospital, Onomichi, Japan.
Daisuke SumitaniDepartment of Surgery, Kenritsu Futabanosato Byoin, Hiroshima, Japan.
Wataru ShimizuDepartment of Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
Mohei KohyamaDepartment of Surgery, Hiroshima General Hospital, Hatsukaichi, Japan.
Yasufumi SaitoDepartment of Surgery, Kure Kyosai Hospital, Kure, Japan.
Shoichiroh MukaiDepartment of Surgery, Chugoku Rosai Hospital, Kure, Japan.
Yuzo HirataDepartment of Surgery, Saiseikai Hiroshima Hospital, Hiroshima, Japan.
Masatoshi KochiDepartment of Gastrointestinal Surgery, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.
Yosuke ShimizuDepartment of Surgery, National Hospital Organization Kure Medical Center, Kure, Japan.
Yuji TakakuraDepartment of Surgery, Chuden Hospital, Hiroshima, Japan.
Masanori YoshimitsuDepartment ofSurgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Shinya KodamaDepartment of Surgery, Yoshida General Hospital, Akitakata, Japan.
Shinnosuke UegamiDepartment of Surgery, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Takuya YanoDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshi OkudaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshima Surgical study group of Clinical Oncology (HiSCO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOxaliplatin, a key drug in the treatment of colorectal cancer (CRC), can cause oxaliplatin-induced peripheral neuropathy (OIPN) in a dose-dependent manner. These symptoms can severely affect daily life, and chronic OIPN often limits treatment continuation because of its correlation with the cumulative dose of oxaliplatin. Currently, effective preventive measures are unavailable. However, surgical glove compression therapy may reduce paclitaxel-induced neuropathy, suggesting its potential in preventing OIPN.

methodsThis multicentre, randomised, open-label, phase II/III trial evaluates surgical glove compression therapy to investigate the possible preventive effects of OIPN in patients with CRC receiving adjuvant capecitabine plus oxaliplatin chemotherapy. Patients with stage III CRC undergoing curative surgery will be enrolled and randomised into two groups. The intervention group will wear two layers of tight-fitting surgical gloves from 30 min before to 30 min after oxaliplatin infusion, whereas the control group will receive standard care. The primary endpoint is the incidence of grade ≥2 chemotherapy-induced peripheral neuropathy (CIPN) based on the Common Terminology Criteria for Adverse Events criteria. Secondary endpoints include quality of life assessments (Functional Assessment of Cancer Therapy/Gynecological Oncology Group-Neurotoxicity-12 and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-item), duration and extent of OIPN as assessed using the Debiopharm Neurologic and Sensory Toxicity Criteria, chemotherapy completion rates, and adverse events. To detect a significant reduction in the incidence of CIPN, 170 patients will be enrolled (36% in the control group vs 15% in the intervention group). The planned case enrolment period is from 1 November 2024 to 31 October 2026. ETHICS AND DISSEMINATION: This trial was approved by the Institutional Review Board of Hiroshima University, Japan (approval no. CRB2024-0008), and has been registered with the Japan Registry of Clinical Trials (jRCTs062240066). The results of this study will be submitted for publication in a peer-reviewed journal and shared with the scientific community at international conferences. TRIAL REGISTRATION NUMBER: jRCTs062240066.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsGloves, SurgicalOxaliplatinPeripheral Nervous System DiseasesAdultCapecitabineClinical Trials, Phase III as TopicFemaleHumansJapanMaleMiddle AgedMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicAntineoplastic AgentsCapecitabineOxaliplatinCHEMOTHERAPYColorectal surgeryGastrointestinal tumours

Identifiers

PMID41698721
PMCPMC12911683

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.